Patents Assigned to SULFATEQ B.V.
  • Patent number: 11730741
    Abstract: The present invention relates to the (S) enantiomeric form of certain 6-chromanol derivatives for use as a medicament. Especially, the present invention relates to the (S) enantiomeric form of a 6-chromanol derivative for use as a medicament wherein said 6-chromanol derivative is chosen from the group consisting of (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone; N-(benzyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; N-(phenyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; methyl 4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamido)benzoate; (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(morpholino)methanone, and pharmaceutically acceptable salts or bases thereof and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: August 22, 2023
    Assignee: SULFATEQ B.V.
    Inventors: Robert Henk Henning, Gerrit Jan Willem Euverink, Guido Krenning, Adrianus Cornelis Van der Graaf
  • Patent number: 11006626
    Abstract: This invention is related to a compound with the structural formula (I) wherein, R1, and R2 are independently selected from the group consisting of C1-C6 alkyl and is preferably methyl, ethyl, propyl or isopropyl; R3 is selected from the group consisting of CH2NHR9, C(?O)YR10, —CH2OH
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: May 18, 2021
    Assignee: Sulfateq B.V.
    Inventors: Adrianus Cornelis Van Der Graaf, Andre Heeres, Johannes Paulus Gerardus Seerden
  • Patent number: 10676452
    Abstract: The present invention relates to compounds for prophylaxis or treatment of organ damage by restoring endothelial function and/or inhibiting reactive oxygen species production and especially to compounds for prophylaxis or treatment of diabetic kidney damage. Specifically, the present invention relates to 6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the prophylaxis or treatment of organ damage by restoring endothelial function and/or inhibiting reactive oxygen species production and especially diabetic kidney organ damage.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: June 9, 2020
    Assignee: Sulfateq B.V.
    Inventors: Adrianus Cornelis Van Der Graaf, Robert Henk Henning, Leo Edwin Deelman, Gerrit Jan Willem Euverink
  • Patent number: 10426771
    Abstract: The present invention relates to compounds for the treatment of chronic obstructive airway diseases such as chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis. The present invention further relates to drug deliver devices suitable to be used in the treatment of chronic obstructive airway diseases such as a nebulizer comprising the present compounds. Specifically, the present invention relates to (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl) (piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the treatment of chronic obstructive airway diseases, preferably chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis, more preferably chronic obstructive pulmonary disease (COPD).
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: October 1, 2019
    Assignee: Sulfateq B.V.
    Inventors: Adrianus Cornelis Van der Graaf, Martina Schmidt, Gerrit Jan Willem Euverink, Hermanus Meurs, Robert Henk Henning
  • Patent number: 10322124
    Abstract: The present invention relates to compounds for the treatment of chronic obstructive airway diseases such as chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis. The present invention further relates to drug delivery devices suitable to be used in the treatment of chronic obstructive airway diseases such as a nebulizer comprising the present compounds. Specifically, the present invention relates to (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the treatment of chronic obstructive airway diseases, preferably chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis, more preferably chronic obstructive pulmonary disease (COPD).
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: June 18, 2019
    Assignee: Sulfateq B.V.
    Inventors: Adrianus Cornelis Van der Graaf, Martina Schmidt, Gerrit Jan Willem Euverink, Hermanus Meurs, Robert Henk Henning
  • Patent number: 10123529
    Abstract: This invention is related to a compound with the structural formula (I) wherein, R1, and R2 are independently selected from the group consisting of C1-C6 alkyl and is preferably methyl, ethyl, propyl or isopropyl; R3 is selected from the group consisting of CH2NHR9, C(?O)YR10, —CH2OH
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: November 13, 2018
    Assignee: Sulfateq B.V.
    Inventors: Adrianus Cornelis Van Der Graaf, Andre Heeres, Johannes Paulus Gerardus Seerden
  • Publication number: 20180280384
    Abstract: The present invention relates to compounds for the treatment of chronic obstructive airway diseases such as chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis. The present invention further relates to drug deliver devices suitable to be used in the treatment of chronic obstructive airway diseases such as a nebulizer comprising the present compounds. Specifically, the present invention relates to (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl) (piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the treatment of chronic obstructive airway diseases, preferably chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis, more preferably chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: January 26, 2018
    Publication date: October 4, 2018
    Applicant: Sulfateq B.V.
    Inventors: Adrianus Cornelis Van der Graaf, Martina Schmidt, Gerrit Jan Willem Euverink, Hermanus Meurs, Robert Henk Henning
  • Publication number: 20180250294
    Abstract: The present invention relates to compounds for the treatment of chronic obstructive airway diseases such as chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis. The present invention further relates to drug delivery devices suitable to be used in the treatment of chronic obstructive airway diseases such as a nebulizer comprising the present compounds. Specifically, the present invention relates to (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the treatment of chronic obstructive airway diseases, preferably chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis, more preferably chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: January 26, 2018
    Publication date: September 6, 2018
    Applicant: Sulfateq B.V.
    Inventors: Adrianus Cornelis Van der Graaf, Martina Schmidt, Gerrit Jan Willem Euverink, Hermanus Meurs, Robert Henk Henning
  • Publication number: 20180170892
    Abstract: The present invention relates to compounds for prophylaxis or treatment of organ damage by restoring endothelial function and/or inhibiting reactive oxygen species production and especially to compounds for prophylaxis or treatment of diabetic kidney damage. Specifically, the present invention relates to 6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the prophylaxis or treatment of organ damage by restoring endothelial function and/or inhibiting reactive oxygen species production and especially diabetic kidney organ damage.
    Type: Application
    Filed: May 12, 2016
    Publication date: June 21, 2018
    Applicant: Sulfateq B.V.
    Inventors: Adrianus Cornelis VAN DER GRAAF, Robert Henk HENNING, Leo Edwin DEELMAN, Gerrit Jan Willem EUVERINK
  • Patent number: 9913841
    Abstract: The present invention relates to compounds for the treatment of chronic obstructive airway diseases such as chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis. The present invention further relates to drug delivery devices suitable to be used in the treatment of chronic obstructive airway diseases such as a nebulizer comprising the present compounds. Specifically, the present invention relates to (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-di-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the treatment of chronic obstructive airway diseases, preferably chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis, more preferably chronic obstructive pulmonary disease (COPD).
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: March 13, 2018
    Assignee: Sulfateq B.V.
    Inventors: Adrianus Cornelis Van der Graaf, Martina Schmidt, Gerrit Jan Willem Euverink, Hermanus Meurs, Robert Henk Henning
  • Publication number: 20150342174
    Abstract: This invention is related to a compound with the structural formula (I) wherein, R1, and R2 are independently selected from the group consisting of C1-C6 alkyl and is preferably methyl, ethyl, propyl or isopropyl; R3 is selected from the group consisting of CH2NHR9, C(?O)YR10, —CH2OH
    Type: Application
    Filed: December 18, 2013
    Publication date: December 3, 2015
    Applicant: SULFATEQ B.V.
    Inventors: Adrianus Cornelis VAN DER GRAAF, Andre HEERES, Johannes Paulus Gerardus SEERDEN
  • Publication number: 20130203830
    Abstract: The invention is related to compounds for prevention of cell injury or protection of cells. The compounds are involved in the maintenance or the increase of hydrogen sulphide in cells, which results in a protection of the cells or the prevention of cell injury. The compounds of the invention can be used in cell culture and tissue culture techniques. They can also be used in several medical conditions such as ischemia, reperfusion and hypothermia, or for preserving organs which are used for transplantation.
    Type: Application
    Filed: April 18, 2011
    Publication date: August 8, 2013
    Applicant: SULFATEQ B.V.
    Inventors: Fatemeh Talaei, Robert Henk Henning, Adrianus C. Van der Graaf